137 related articles for article (PubMed ID: 11642306)
21. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
22. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
23. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
24. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
25. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
Nadav L; Eldor A
Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
[TBL] [Abstract][Full Text] [Related]
26. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
27. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
28. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
29. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
32. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
[No Abstract] [Full Text] [Related]
33. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
34. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
35. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Abruzzese E; Cantonetti M; Morino L; Orlandi G; Tendas A; Del Principe MI; Masi M; Amadori S; Orlandi A; Anemona L; Campione E
J Clin Oncol; 2003 Nov; 21(22):4256-8. PubMed ID: 14615464
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
37. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Shah NP; Sawyers CL
Oncogene; 2003 Oct; 22(47):7389-95. PubMed ID: 14576846
[TBL] [Abstract][Full Text] [Related]
38. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
[TBL] [Abstract][Full Text] [Related]
39. Cancer biology: summing up cancer stem cells.
Huntly BJ; Gilliland DG
Nature; 2005 Jun; 435(7046):1169-70. PubMed ID: 15988505
[No Abstract] [Full Text] [Related]
40. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]